Cargando…
Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats
OBJECTIVE: To develop and evaluate zolmitriptan spanlastics (Zol SLs) as a brain-targeted antimigraine delivery system. Spanlastics (SLs) prepared using span 60: tween 80 (70:30%, respectively) gave the highest percentage of entrapment efficiency (EE%). MATERIALS AND METHODS: A total of 60 adult mal...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877729/ https://www.ncbi.nlm.nih.gov/pubmed/31819367 http://dx.doi.org/10.2147/DDDT.S220473 |
_version_ | 1783473395197804544 |
---|---|
author | El-Nabarawy, Nagla Ahmed Teaima, Mahmoud Hassan Helal, Doaa Ahmed |
author_facet | El-Nabarawy, Nagla Ahmed Teaima, Mahmoud Hassan Helal, Doaa Ahmed |
author_sort | El-Nabarawy, Nagla Ahmed |
collection | PubMed |
description | OBJECTIVE: To develop and evaluate zolmitriptan spanlastics (Zol SLs) as a brain-targeted antimigraine delivery system. Spanlastics (SLs) prepared using span 60: tween 80 (70:30%, respectively) gave the highest percentage of entrapment efficiency (EE%). MATERIALS AND METHODS: A total of 60 adult male Wistar albino rats were divided into six groups (n=10 rats/group). Group 1 (Control) comprised rats serving as a negative control. Group 2 was treated with glyceryl trinitrate (NTG) and served as the positive control. Groups 3 (NTG+Zol com), Group 4 (NTG+Zol sol) and Group 5 (NTG+Zol SLs) received commercial zolmitriptan orally, zolmitriptan solution intranasally and Zol SLs F5 intranasally, respectively, 30 min before NTG. Group 6 (Zol SLs) comprised normal rats that received only Zol SLs intranasally. RESULTS: We found decreased T(max), increased C(max), AUC(0–6), AUC(0–∞ and) ameliorated behaviour in rats (head scratching) treated with intranasal SLs compared to oral commercial zolmitriptan. CONCLUSION: Our study substantiates the enhanced efficacy of Zol SLs in brain targeting for migraine treatment. |
format | Online Article Text |
id | pubmed-6877729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-68777292019-12-09 Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats El-Nabarawy, Nagla Ahmed Teaima, Mahmoud Hassan Helal, Doaa Ahmed Drug Des Devel Ther Original Research OBJECTIVE: To develop and evaluate zolmitriptan spanlastics (Zol SLs) as a brain-targeted antimigraine delivery system. Spanlastics (SLs) prepared using span 60: tween 80 (70:30%, respectively) gave the highest percentage of entrapment efficiency (EE%). MATERIALS AND METHODS: A total of 60 adult male Wistar albino rats were divided into six groups (n=10 rats/group). Group 1 (Control) comprised rats serving as a negative control. Group 2 was treated with glyceryl trinitrate (NTG) and served as the positive control. Groups 3 (NTG+Zol com), Group 4 (NTG+Zol sol) and Group 5 (NTG+Zol SLs) received commercial zolmitriptan orally, zolmitriptan solution intranasally and Zol SLs F5 intranasally, respectively, 30 min before NTG. Group 6 (Zol SLs) comprised normal rats that received only Zol SLs intranasally. RESULTS: We found decreased T(max), increased C(max), AUC(0–6), AUC(0–∞ and) ameliorated behaviour in rats (head scratching) treated with intranasal SLs compared to oral commercial zolmitriptan. CONCLUSION: Our study substantiates the enhanced efficacy of Zol SLs in brain targeting for migraine treatment. Dove 2019-11-21 /pmc/articles/PMC6877729/ /pubmed/31819367 http://dx.doi.org/10.2147/DDDT.S220473 Text en © 2019 El-Nabarawy et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research El-Nabarawy, Nagla Ahmed Teaima, Mahmoud Hassan Helal, Doaa Ahmed Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats |
title | Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats |
title_full | Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats |
title_fullStr | Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats |
title_full_unstemmed | Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats |
title_short | Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats |
title_sort | assessment of spanlastic vesicles of zolmitriptan for treating migraine in rats |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877729/ https://www.ncbi.nlm.nih.gov/pubmed/31819367 http://dx.doi.org/10.2147/DDDT.S220473 |
work_keys_str_mv | AT elnabarawynaglaahmed assessmentofspanlasticvesiclesofzolmitriptanfortreatingmigraineinrats AT teaimamahmoudhassan assessmentofspanlasticvesiclesofzolmitriptanfortreatingmigraineinrats AT helaldoaaahmed assessmentofspanlasticvesiclesofzolmitriptanfortreatingmigraineinrats |